Disposition of 12342 shares by Valerie Morisset of Eliem Therapeutics at 7.06 subject to Rule 16b-3

ELYMDelisted Stock  USD 3.09  0.06  1.90%   
About 60% of Eliem Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Eliem Therapeutics suggests that many traders are alarmed regarding Eliem Therapeutics' prospects. Eliem Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Eliem Therapeutics. Many technical investors use Eliem Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Eliem Therapeutics Officer: Evp, R&d And Cso. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 12342 common stock at 7.06 of Eliem Therapeutics by Valerie Morisset on 5th of July 2024. This event was filed by Eliem Therapeutics with SEC on 2024-07-05. Statement of changes in beneficial ownership - SEC Form 4

Eliem Therapeutics Fundamental Analysis

We analyze Eliem Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

Eliem Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Eliem Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eliem Therapeutics stock to make a market-neutral strategy. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics with similar companies.

Peers

Eliem Therapeutics Related Equities

ADAGAdagene   3.40   
0%
52.0%
ACRVAcrivon Therapeutics,   2.71   
0%
42.0%
CSBRChampions Oncology   2.40   
0%
37.0%
STTKShattuck Labs   1.75   
0%
27.0%
AVTEAerovate Therapeutics   0.78   
0%
12.0%
PHVSPharvaris   0.65   
0%
10.0%
MNOVMediciNova   0.47   
0%
7.0%
ANTXAN2 Therapeutics   0.00   
0%
0%
MOLNMolecular Partners   0.75   
11.0%
0%
RZLTRezolute   1.11   
17.0%
0%
HCWBHCW Biologics   1.14   
17.0%
0%
PMVPPmv Pharmaceuticals   1.92   
29.0%
0%
PEPGPepGen   3.99   
62.0%
0%
IPSCCentury Therapeutics   4.92   
76.0%
0%
ANEBAnebulo Pharmaceuticals   6.43   
100.0%
0%
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in Eliem Stock

If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm